Skip to main
GOSS
GOSS logo

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. is supported by overwhelmingly positive key opinion leader (KOL) sentiment, particularly regarding the anticipated success of PROSERA in treating pulmonary arterial hypertension (PAH), with projected treatment effects ranging between 25 to 30 meters in the 6-minute walk distance (6MWD). The phase 2 TORREY trial data displayed consistent benefits across various endpoints, demonstrating reductions in pulmonary vascular resistance (PVR) and pro-BNP levels, alongside a notable increase in 6MWD, suggesting strong therapeutic potential for the company's product pipeline. Engagement from investors at recent conferences reflects heightened interest in Gossamer Bio, driven by encouraging data and optimistic expert commentary.

Bears say

Gossamer Bio Inc. faces a negative outlook as the market continues to misprice the odds of success for its leading candidate, Seralutinib, despite a recent increase in stock value. This mispricing indicates potential overvaluation, raising concerns about the sustainability of the stock’s upward momentum. Additionally, the reliance on a clinical-stage pipeline without fully realized or commercialized products poses inherent risks that could negatively affect the company's financial stability.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.